AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06061926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celery Seed
Description: Celery seed capsules (Apium graveolens L.) 150 mg twice times at day, one capsule with 75 mg before breakfast and one capsule with 75 mg before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Study NCT06061926 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules (calcined magnesia) twice times at day, one capsule before breakfast and one capsule before dinner during 12 weeks. Homologated to the other intervention. Oral administration.
Study NCT04840641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flucloxacillin
Description: Healthy volunteers will take 2x500 mg flucloxacillin 3 times a day for 31 days. The investigators will measure the baseline concentration of the 6-cocktaildrugs and flucloxacillin before start of 31 days of flucloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of flucloxacillin. On day 10 and 28 the investigators will measure the concentration of the 6 cocktaildrugs
Study NCT05620368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Compassionate Living Course (MCLC)
Description: The course will be held online (using the Zoom platform) with weekly sessions lasting 2.5 hours each, as well as a day of silent practice (mini-retreat of 4 hours) between sessions 6 and 7.~On the structural level, every course session consists of four elements: (1) an educational input, (2) mindfulness and compassion exercises (eg, sitting meditation, body scan, mindful walking, self-compassion break), (3) a reflection of one's practice (inquiry), (4) and home assignments.
Study NCT05620368 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care intervention
Description: If necessary, psychological support is organized at the request of the parent.~Support includes individual support of a psychologist (1h / week), consultation with a teacher (special pedagogue and early school education teacher, 1h / week), individual consultation with observation of a child with a Venetian mirror (1h / week).
Study NCT05097027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction recovery
Description: Soccer players included in experimental group I will carry out this program for 1 week setting the blood pressure to \~ 60% of limb occlusion pressure (LOP). After a month they will carry out the program without restriction of blood flow. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
Study NCT05097027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active recovery
Description: Soccer players included in experimental group II will carry out this program for 1 week. After a month they will carry out the program with blood flow restriction. Which will consist of a warm-up part with continuous running (5 min), 6 sprints from box to box of the field at 60-70% of a maximum repetition, and an activation part in the form of rounds with the ball.
Study NCT04988815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b
Description: Eligible subjects will receive Ropeginterferon alfa-2b subcutaneously (SC) every 2 weeks at the starting dose of 250µg at week 0, 350 µg at week 2, then 500µg at a fixed dose from week 4 onwards
Study NCT03924908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VRH
Description: Patients will see a 3D film combined with a hypnotic voice during the entire procedure of dressing change
Study NCT03924908 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VR
Description: Patients will see a 3D film without any hypnotic voice during the entire procedure of dressing change
Study NCT06089889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ice application
Description: * Group 1 will undergo the first intervention, which involves the application of ice.~* Ice pack will be applied on the site of venipuncture prior to intravenous procedures for 3 minutes.~* The procedure of venous puncture will be carried out in accordance with established standard operating procedures (SOPs).~* pain will be assessed through Wong baker Faces Pain scale immediate after venous puncture procedure.~after taking consent from parents/guardians, the pain response of children will be video taped for the purpose of objectively assessing the pain. and data will be kept confidential.
Study NCT06089889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: * Group 2 will be control group, which involves no ice application~* The venipuncture procedure will be carried out according to established standard operating procedures (SOPs), pain will be assessed by Wong Baker Faces Pain Scale immediate after venous puncture procedure.~After obtaining consent from parents/guardians, the pain responses of children will be videotaped for the purpose of objectively assessing pain, and the data will be kept confidential.
Study NCT05918250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-2736
Description: mRNA-2736 will be administered IV.
Study NCT05254574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm@ with 2.5% Diclofenac patches.
Study NCT05254574 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sustained Acoustic Device with 0% Diclofenac Patch
Description: Patients apply the placebo SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% Diclofenac patches.
Study NCT05254574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Diclofenac Topical Gel
Description: Topical pain-relief gel
Study NCT06319456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisaftoclax (APG-2575)
Description: QD, oral administration, every 28 days for a dosing cycle.
Study NCT06319456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: BID, oral administration, every 28 days for a dosing cycle.
Study NCT06319456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Study NCT06319456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide，CTX
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Study NCT06319456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Study NCT06319456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorambucil
Description: Every 28 days for a treatment cycle, administration of 6 cycles.
Study NCT06380855 — intervention group
Intervention type: PROCEDURE
Intervention: Flexible colonoscope assisted hybrid transanal total mesorectal resection
Description: Endoscopic pursestring suture (EPSS) was performed at the distance from 1cm to the inferior edge of the tumor by a double-channel flexible colonoscope. An endoloop was inserted through one channel. Meanwhile, the endoclips was inserted through the other channel one by one to fix the endoloop around the rectal wall. And then the endoloop was tightened slowly. After completing the routine lavage lumen, a full-thickness, circumferential dissection was performed by flexible colonoscope following taTME surgical principle until it converged with the laparoscopy group.
Study NCT05584787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soractelite Echolaser Transperineal focal laser ablation
Description: US/MRI fusion laser ablation of low- and intermediate risk prostate cancer
Study NCT06609720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (guided tissue regeneration)
Description: Randomized clinical and radiographic trial
Study NCT05717608 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Description: oral ingestion of food supplement for 4 weeks
Study NCT05717608 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high vs low fructose in caucasian dutch or surinamese asian type 2 diabetes subjects
Description: oral ingestion of food supplement for 4 weeks
Study NCT05468346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-HEC585
Description: Single Dose = Solution containing 200 mg/100 µCi \[14C\]-HEC585
Study NCT04694430 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample
Description: 2 ml venous blood was collected and separated into serum.
Study NCT04694430 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: 1. Whether the patient has been vaccinated with DPT vaccine and record the time of vaccination;~2. Medication situation of patients in the past year, including rescue drugs, antitussive and expectorant drugs, inhaled corticosteroids and antibiotics;~3. Assess COPD using ABCD assessment tool.
Study NCT04694430 — intervention group
Intervention type: PROCEDURE
Intervention: Throat swab
Description: Before the collection of oropharyngeal swabs, instruct the patient to wash the mouth or gargle, fix the patient's head, open the mouth and expose the throat. If necessary, use a tongue depressor to gently press the tongue.~Use the swab to wipe the secretion on both sides of the palatal arch, pharynx and tonsil with a sensitive and gentle action, and quickly withdraw the swab to avoid contacting other parts of the mouth.~Put the swab in the sterile test tube, plug the opening with cotton ball, and send it for inspection and registration in time.
Study NCT05448612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Release Technique and muscle energy technique
Description: 74 participants divided into two groups and 37 in each group.
Study NCT05731453 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Polygenetic risk score
Description: Polygenetic risk score assessment for breast cancer
Study NCT05874154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tibial nerve selective neurotomy
Description: Patients in the STN group will undergo a pre-anaesthetic visit before surgery to validate the possibility of general anesthesia. The surgery will be performed at maximum 3 months after inclusion. The muscles that have been defined pre-randomization will be targeted by the surgery. The duration of the surgery is about 1 hour and 30 minutes.
Study NCT05874154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin injection
Description: Patients in the BoNT group will be treated with BoNT A under electromyography, electrical stimulation and/or ultrasound guidance (V0). In the absence of scientific evidence between the efficacy of onabotulinumtoxin A and abobotulinumtoxin A, physician will be free to choose between these two BoNT formulation which are both authorized for the treatment of lower limb spasticity. The physician will determine the muscles targeted by the BoNT (gastrocnemius and soleus for equinus, posterior tibialis for varus, and long flexor digitorum and flexor hallucis for claw toes), the appropriate dose and dilution based on his experience, following a semi-guided table of equivalence for respective doses of onabotulinumtoxin A and abobotulinumtoxin A. A delay superior to 3 months will be respected after the last injection and the muscles that have been defined pre-randomization will be targeted by injections.
Study NCT04311099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active drug
Description: Injection of Ropivacaine
Study NCT04311099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Injection of Saline solution
Study NCT04311099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Saline solution
Study NCT04311099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Ropivacaine - Ultrasound-guided transverse abdominal plane block
Description: Lateral ultrasound-guided transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
Study NCT04311099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of Ropivacaine - Laparoscopic assisted transverse abdominal plane block
Description: Laparoscopic assisted subcostal transverse abdominal plane block 40 ml ropivacaine 2 mg / ml
Study NCT04311099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of placebo - Ultrasound-guided transverse abdominal plane block
Description: Lateral ultrasound-guided transverse abdominal plane block with saline solution
Study NCT04311099 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo - Ultrasound-guided transverse abdominal plane block
Description: Lateral ultrasound-guided transverse abdominal plane block with saline solution
Study NCT04311099 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Injection of placebo - Laparoscopic assisted transverse abdominal plane block
Description: Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
Study NCT04311099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Injection of placebo - Laparoscopic assisted transverse abdominal plane block
Description: Laparoscopic assisted subcostal transverse abdominal plane block with saline solution
Study NCT05146882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belcesiran
Description: Belcesiran will be administered subcutaneously (SC) in the treatment arm.
Study NCT05916235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THOR® laser system
Description: We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
Study NCT05916235 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: THOR® laser system
Description: We chose the THOR® laser system given because their active treatment arm uses both coherent laser and monochromatic LED light. Therefore, we will use three types of active probes in this investigation including, A) Single Laser 810 NM 200 mw; B) Laser Cluster of 810 NM equivalent to 1 WATT and; C) LED Cluster, 34 X 660nm at 10 mw and 35 850nm, 30mw 1390mw total. As detailed in Table 3. We propose to use these three PBM probes in concert for the treatment of TMD pain. Laser A (Single Diode Laser) is designed for isolated trigger points and superficial muscles. Laser B (Cluster Laser) is designed for a more diffuse treatment area,targeting analgesia, anti-inflammatory, and deep tissue repair. Laser C (LED Cluster) is purportedly designed for the presence of diffuse inflammation.
Study NCT06080334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling using the Hong technique on the most hyperalgesic trigger point in the gastrocnemius muscle.
Study NCT06080334 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolysis
Description: Electrolysis on the Achilles tendon using ultrasound-guided technique.
Study NCT06263582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate pessary
Description: Subjects will use the study pessaries, placed in the vagina every day for 5 consecutive days.
Study NCT06263582 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood draws for pharmacokinetics of the study drug
Description: On day 5, all participants will have their blood draws before they use the pessary, and at 15 min, 30 mins, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after inserting the pessary. Blood samples will be tested for the pharmacokinetics of the study drug.
Study NCT06345690 — intervention group
Intervention type: OTHER
Intervention: VIA Disc NP
Description: VIA Disc NP - Allograft tissue injection
Study NCT04800276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle strengthening targeted on ischemic areas
Description: muscle strengthening targeted on ischemic areas
Study NCT04800276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: global muscle strenghtening
Description: global muscle strenghtening
Study NCT06065670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: 12 or 8 mg Clemastine tablet. Clemastine fumarate was approved by the Food and Drug Administration (FDA) for the treatment of allergic rhinitis (seasonal allergies) in 1977 and was approved for over-the-counter marketing in 1992. Clemastine is not FDA approved as a remyelinating therapy
Study NCT06065670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matched sugar tablet
Study NCT06202482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connect Active Program
Description: Younger adults will help older adults increase their digital literacy, skills, and desire to exercise and become more physically active via the proposed intervention. The Connect Active Program will consist of two components: walking exercises and mobile apps.
Study NCT05794958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
Study NCT05794958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axicabtagene Ciloleucel
Description: Subjects will receive a re-infusion of Axi-Cel (Axi-Cel-2) if signs and symptoms of cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are ≤ grade 1.
Study NCT05756179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin and Hesperidin Combination
Description: Diosmin 450 mg and Hesperidin 50 mg Combination
Study NCT06477120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Eating
Description: The time-restricted eating arm will be instructed to eat ad libitum during an 8-hr window daily 11am - 7pm in the 2nd trimester and 10-hr eating window from 10am - 8pm in the 3rd trimester and abstain from caloric foods and beverages for the remaining 14-16 hours.
Study NCT05227105 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity will be encouraged up to an amount of 150 minutes per week.
Study NCT06425458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Co-Designed Strengths-Based Leadership Program
Description: Please see arm description.
Study NCT06347380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FemPulse System
Description: Subjects to receive the FemPulse System consisting of a non-implanted, vaginal electrical stimulation device (Ring) and other patient accessories.
Study NCT05227105 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed intervention
Description: Physical activity will be encouraged at the end of the trial.
Study NCT06653075 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mandibular advancement with acrylic splint Herbst Appliance
Description: Mandibular advancement with acrylic splint Herbst Appliance
Study NCT06653075 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mandibular advancement with acrylic splint Herbst Appliance
Description: Mandibular advancement with acrylic splint Herbst Appliance
Study NCT06653998 — intervention group
Intervention type: OTHER
Intervention: Early mobilization and rehabilitation
Description: In the initial assessment will be applied the ICU Mobility Scale, with the objective of establishing the patient\&#39;s current level of function and determining the most appropriate type, intensity and duration of activity.~The sessions, which will be conducted by a physiotherapist, will include therapeutic strategies such as bed exercises (both active and passive), electrical stimulation, use of an in-bed cycloergometer (for upper and lower limbs), sitting on the edge of the bed, bed transfers, bedside transfers from bed to chair, out-of-bed exercises, standing, and walking. The latter two activities are considered to be the most complex. Each session will last approximately 20 to 30 minutes and will be conducted once a day, on a daily basis throughout the patient\&#39;s ICU stay. The last session wil be prior to discharge of the patient.~During each session, the Borg Perception of Exertion Scale will be assessed in order to adjust the intensity of physical activity.
Study NCT06654362 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional interventions include education and modifying company's restaurant menu
Description: * Reducing fried foods and replacing them with healthier alternatives.~* Decreasing the consumption of sweetened beverages such as soda and replacing them with yogurt.~* Reducing the intake of refined grains and substituting with whole grains.~* Increasing fruit intake.~* Increasing the intake of vegetables as much as possible.~* Organizing face-to-face educational sessions with the chef to train them and improve cooking methods, to reduce fat and oil intake.
Study NCT06654596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 240mg
Description: Patients in telitacicept group will be treated with maximum tolerable dose of angiotensin converting enzyme inhibitor ( ACEI ) and/or angiotensin II receptor blocker ( ARB ) combined with telitacicept. 240 mg telitacicept will be used once a week for 40 weeks.